

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Vitana-X Inc

515 E Las Olas Boulevard Suite 120, FL 33301 Fort Lauderdale.

+1 352 578 1642

<https://vitanax.net/en/>

finance@vitanax.com

SIC Code: 5499

Quarterly Report

For the Period Ending: January 31, 2021

(the "Reporting Period")

As of January 31, 2021, the number of shares outstanding of our Common Stock was: 1,354,502,045

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Current name: Vitana-X Inc (Name change effective on FINRA by December 30, 2020)

Previous name: GH-Capital Inc

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Florida, active

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change, or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

The address(es) of the issuer’s principal executive office:

515 E Las Olas Boulevard Suite 120, FL 33301 Fort Lauderdale. U.S

The address(es) of the issuer’s principal place of business:

Check box if principal executive office and principal place of business are the same address:

Same as above

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

2) Security Information

Trading symbol:	<u>VITX</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>92850X105</u>	
Par or stated value:	<u>\$0.0001</u>	
Total shares authorized:	<u>5,000,000,000</u>	as of date: <u>01/31/2021</u>
Total shares outstanding:	<u>1,354,502,045</u>	as of date: <u>01/31/2021</u>
Number of shares in the Public Float ² :	<u>1,294,672,092</u>	as of date: <u>01/31/2021</u>
Total number of shareholders of record:	<u>39</u>	as of date: <u>01/31/2021</u>

All additional class(es) of publicly traded securities (if any): N/A

Transfer Agent

Name: West Coast Stock Transfer, Inc.
Phone: 619.664.4780
Email: cs@wcsti.com
Address: 721 N. Vulcan Ave. Suite 106
Encinitas, CA 92024

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Shares Outstanding as of Second Most Recent Fiscal Year End: 07/31/2019 Opening Balance Common: <u>339,573,445</u> Preferred:			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>03/04/19</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Series A Preferred</u>		<u>No</u>	<u>Dirk Richter</u>	<u>Founder Shares</u>	<u>Restricted</u>	<u>Section 4a2</u>
<u>03/04/19</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Series A Preferred</u>		<u>No</u>	<u>Bernhard Sammer</u>	<u>Founder Shares</u>	<u>Restricted</u>	<u>Section 4a2</u>
<u>05/30/19</u>	<u>New Issuance</u>	<u>10,200,000</u>	<u>Common</u>		<u>No</u>	<u>Tysadco Partners (1)</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Rule 506(b)</u>
<u>06/24/20</u>	<u>Cancellation</u>	<u>-7,000,000</u>	<u>Common</u>		<u>No</u>	<u>Wolfgang Ruecker</u>		<u>Restricted</u>	<u>Regulation S</u>
<u>02/08/21</u>	<u>New Issuance</u>	<u>11,500,000</u>	<u>Common</u>		<u>No</u>	<u>Crown Bridge Partners LLC (2)</u>	<u>Funding</u>	<u>Restricted</u>	<u>Rule 506(b)</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>4,524.8</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Thomas Tork</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>48,380.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Central Park Investment LLP (3)</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Rule 506(b)</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>1,129.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Marco Djuricin</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>

<u>04/07/21</u>	<u>New Issuance</u>	<u>8,052.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Wolfgang Martinschitz</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>4,031.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Christian Moenninghoff</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>4,031.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Jan Papenbrock</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>1,359.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Jurgen Hofbauer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>683.8</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Michael Decker</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>1,517.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Regina Angel</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>226.4</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Wolfgang Litschauer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>567.8</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Elisabeth Grotzl</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>227</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Lukas Grotzl</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>1,362.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Thomas Stangl</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>454.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Thomas Hofbauer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>454</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Alois Hofbauer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>1,134.4</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Bernhard Zimmerl</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>1,139.5</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Wolfgang Mayerhofer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>1,139.9</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Helga Wagner</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>683.9</u>	<u>Series B Preferred</u>		<u>No.</u>	<u>Thomas Waldher</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>340.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Thomas Morak</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
<u>04/07/21</u>	<u>New Issuance</u>	<u>10,480.8</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Jacobus Willem Johannes Van der Eijk</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>

04/07/21	<u>New Issuance</u>	<u>2,701.4</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Steffi Macown</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,612.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Erich Zullig</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>566</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Josef El Assal</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,491.6</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Christoph Goeth</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>566.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Stefan Mang</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>211.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Gerald Bock</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>455.6</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Marcus Weissenbock</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>459.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Maximilian Horhager</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,146</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Kurt Ortner</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>5,660.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Johann Podlipnig</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,588.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Alexander Rudiger</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,839.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Stephan Lukas Podlipnig</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>5,656.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>David Podlipnig</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,839.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Sabrina Podlipnig</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>681.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Diana Brandt</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,809.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Michael Hofer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>453</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Mike Pfeiffer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,582.5</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Goran Djuricin</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>

04/07/21	<u>New Issuance</u>	<u>1,804.8</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Karl Heinz Jamnig</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>224.6</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Daniel Bichler</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>204.4</u>	<u>Series B Preferred</u>		<u>No</u>	<u>René Simmen</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,259.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Wolfgang Bartsch</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>225.8</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Claudia Monay</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>450.9</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Jan Niklas Hadler</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,083.6</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Manfred Feiertag</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>5,039.6</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Benjamin Heyny</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>415.9</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Jurg Zullig</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,130.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Karl Weixelbauer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>224.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Pascal Kitzmueller</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>16,126.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Michael Putz</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>6,450.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Marc-Oliver Richter</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>16,126.7</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Zeliko Sekulic</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,112.9</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Patrick Strobel-Rabitsch</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>604.8</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Jurgen Pollinger</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>806.3</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Peter Bauer</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>22.779</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Matthias Goeth</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>

04/07/21	<u>New Issuance</u>	<u>12,095</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Anna Laura Graefinger</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>10,482.4</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Hanna Valeisha</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>1,935.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Stella Soeldner</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,419</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Theresa Maier-Dobersberger</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,419</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Thomas Richter</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,419</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Robert Rieder</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,419</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Andreas Sammer</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>2,419</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Josef Sammer</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>161,267.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Leonardo Management and Consulting LTD (4)</u>	<u>Cash/Service Agreement</u>	<u>Restricted</u>	<u>Rule 506(b)</u>
04/07/21	<u>New Issuance</u>	<u>80,633.6</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Robert Schimanko</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>504</u>	<u>Series B Preferred</u>		<u>No</u>	<u>René Suess</u>	<u>Service Agreement</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>310.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Robert Hinterleitner</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>215.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Elmar Hanns Ilmberger</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>403.2</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Achim Koehler</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>222.5</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Eckhardt Klas</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>14,514</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Elmar Aichbichler</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>24,190.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Alexander Maringer</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>
04/07/21	<u>New Issuance</u>	<u>215.1</u>	<u>Series B Preferred</u>		<u>No</u>	<u>Patrick Schelter</u>	<u>Cash</u>	<u>Restricted</u>	<u>Regulation S</u>

04/07/21	New Issuance	8,067.4	Series B Preferred		No	Georg Siegfried Blaimauer	Cash	Restricted	Regulation S
04/07/21	New Issuance	444.5	Series B Preferred		No	Martin Kochl	Cash	Restricted	Regulation S
04/07/21	New Issuance	403,167.8	Series B Preferred		No	Dirk Richter	Founder Shares	Restricted	Section 4a2
04/07/21	New Issuance	403,167.8	Series B Preferred		No	Bernhard Sammer	Founder Shares	Restricted	Section 4a2
Shares Outstanding on Date of This Report:									
Ending Balance: Date 08/06/2021									
Common: 1,366,002,045									
Preferred: 1,344,756									

- (1) Robert Delvecchio
- (2) Seth Adhoot
- (3) Michael Ferentinos
- (4) Dirk Richter

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
08/13/19	3,357.00	3,357.00	No interest		0.12	Christoph Klein	Funding
08/14/19	1,026.96	1,026.96	No interest		0.12	Mario Reichmuth	Funding
08/19/19	27,778.96	27,778.96	No interest		0.08	Dietmar Thuller	Funding
09/03/20	3,284.00	3,284.00	No interest		0.08	Nadine Aschgan	Funding
12/15/19	5,576.00	5,576.00	No interest		0.10	Nico Eichler	Funding
12/16/19	5,571.00	5,571.00	No interest		0.08	René Suess	Funding
03/20/20	3,221.00	3,221.00					

12/16/19	<u>8,356.00</u>	<u>8,356.00</u>	<u>No interest</u>		<u>0.10</u>	Valentin Schawerda	<u>Funding</u>
12/18/19	<u>5,558.00</u>	<u>5,558.00</u>					
12/20/19	<u>11,110.00</u>	<u>11,110.00</u>	<u>No interest</u>		<u>0.08</u>	Martin Köchel	<u>Funding</u>
12/20/19	<u>13,897.00</u>	<u>13,897.00</u>	<u>No interest</u>		<u>0.10</u>	Gerald Kronstorfer	<u>Funding</u>
12/20/19	<u>11,022.00</u>	<u>11,022.00</u>	<u>No interest</u>		<u>0.10</u>	David Koch	<u>Funding</u>
12/20/19	<u>10,000.00</u>	<u>10,000.00</u>	<u>No interest</u>		<u>0.10</u>	Victoria Pfeiffer	<u>Funding</u>
12/21/19	<u>5,531.00</u>	<u>5,531.00</u>	<u>No interest</u>		<u>0.10</u>	Stefan Nemeth	<u>Funding</u>
12/23/19	<u>6,650.00</u>	<u>6,650.00</u>	<u>No interest</u>		<u>0.10</u>	Martina Tobisch	<u>Funding</u>
12/27/19	<u>5,573.00</u>	<u>5,573.00</u>	<u>No interest</u>		<u>0.10</u>	Andrea Kagerer	<u>Funding</u>
01/06/20	<u>2,239.00</u>	<u>2,239.00</u>	<u>No interest</u>		<u>0.10</u>	Kai Völkle	<u>Funding</u>
02/07/20	<u>10,981.00</u>	<u>10,981.00</u>	<u>No interest</u>		<u>0.08</u>	Andrea Riedel	<u>Funding</u>
02/07/20	<u>21,959.00</u>	<u>21,959.00</u>	<u>No interest</u>		<u>0.08</u>	Alfred Riedel	<u>Funding</u>
11/08/19	<u>1,539.00</u>	<u>1,539.00</u>	<u>No interest</u>		<u>0.08</u>	Robert Hinterleitner	<u>Funding</u>
03/01/20	<u>2,100.00</u>	<u>2,100.00</u>					
03/01/20	<u>1,114.00</u>	<u>1,114.00</u>					
06/01/20	<u>2,000.00</u>	<u>2,000.00</u>					
03/07/20	<u>5,643.00</u>	<u>5,643.00</u>	<u>No interest</u>		<u>0.10</u>	Michel Ralf	<u>Funding</u>
04/29/20	<u>5,424.00</u>	<u>5,424.00</u>	<u>No interest</u>		<u>0.10</u>	Wolfgang Brader	<u>Funding</u>
05/08/20	<u>10,000.00</u>	<u>10,000.00</u>	<u>No interest</u>		<u>0.10</u>	S+B Mobile Solution- Stephan Roth	<u>Funding</u>
05/02/20	<u>11,119.00</u>	<u>11,119.00</u>	<u>No interest</u>		<u>0.10</u>	Tobias Sommer	<u>Funding</u>
05/12/20	<u>10,823.00</u>	<u>10,823.00</u>	<u>No interest</u>		<u>0.08</u>	Martin Kristler	<u>Funding</u>
05/19/20	<u>10,000.00</u>	<u>10,000.00</u>	<u>No interest</u>		<u>0.10</u>	Christian Zbinden	<u>Funding</u>
06/19/20	<u>10,000.00</u>	<u>10,000.00</u>	<u>No interest</u>		<u>0.10</u>	Beat Caprez	<u>Funding</u>
07/21/20	<u>10,000.00</u>	<u>10,000.00</u>	<u>No interest</u>		<u>0.10</u>	Reinhard Winkler	<u>Funding</u>
09/08/20	<u>5,900,00</u>	<u>5,900,00</u>	<u>No interest</u>		<u>0.08</u>	Rainer Schulte	<u>Funding</u>

09/08/20	2.960,00	2.950,00	<u>No interest</u>		0.08	Michaela Leipnitz	Funding
09/08/20	11.800,00	11.800,00	<u>No interest</u>		0.08	Daniele Zanellato	Funding
09/08/20	6.490,00	6.454,00	<u>No interest</u>		0.08	Maximilian Wirth	Funding
09/08/20	5.900,00	5.900,00	<u>No interest</u>		0.08	Paul Langbroeck	Funding
09/08/20	4.130,00	4.103,00	<u>No interest</u>		0.08	Claudia Balogh	Funding
09/08/20	3.540,00	3.517,00	<u>No interest</u>		0.08	Csaba Mohos	Funding
09/08/20	8.830,00	8.853,75	<u>No interest</u>		0.08	Tanja Huettinger	Funding
09/08/20	8.295,00	8.295,00	<u>No interest</u>		0.08	Karl Heinz Platzer	Funding
09/08/20	7.080,00	7.080,00	<u>No interest</u>		0.08	Mario Waesch	Funding
09/08/20	3.540,00	3.540,00	<u>No interest</u>		0.08	Niklas Graetz	Funding
09/08/20	3.540,00	3.513,00	<u>No interest</u>		0.08	Silvia Fischer	Funding
09/08/20	11.800,00	11.765,00	<u>No interest</u>		0.08	Michaela Himsl- Landgraf	Funding
09/08/20	5.890,00	5.890,00	<u>No interest</u>		0.08	Manuela Knott	Funding
09/08/20	2.950,00	2.896,00	<u>No interest</u>		0.08	Alena Krueger	Funding
09/08/20	3.560,00	3.560,00	<u>No interest</u>		0.08	Brigitte Daniel	Funding
09/08/20	2.970,00	2.970,00	<u>No interest</u>		0.08	Nicole Frauboese	Funding
09/08/20	2.970,00	2.938,00	<u>No interest</u>		0.08	Claudia Koch	Funding
09/08/20	11.800,00	11.805,00	<u>No interest</u>		0.08	Ing. Harald Himsl	Funding
09/08/20	5.900,00	5.902,50	<u>No interest</u>		0.08	Stephan Florian Waitzhofer	Funding
09/08/20	11.800,00	11.805,00	<u>No interest</u>		0.08	Edith Dr. Heller	Funding
09/08/20	2.950,00	2.890,50	<u>No interest</u>		0.08	Stefanie Raddatz	Funding
09/08/20	5.900,00	5.900,00	<u>No interest</u>		0.08	Sascha Seeger	Funding
09/08/20	11.800,00	11.805,00	<u>No interest</u>		0.08	Edith Dr. Heller	Funding
09/08/20	59.000,00	59.000,00	<u>No interest</u>		0.08	Nico Curman	Funding
11/15/20	11.840,00	11.840,00	<u>No interest</u>		0.09	Edith Dr. Heller	Funding

11/15/20	11.840,00	11.765,00	<u>No interest</u>		0.09	Ing. Harald Himsl	Funding
11/16/20	5.920,00	5.760,50	<u>No interest</u>		0.12	Mario Fanto	Funding
11/16/20	11.860,00	11.840,00	<u>No interest</u>		0.09	Kathrin Thaler	Funding
11/16/20	5.920,00	5.734,42	<u>No interest</u>		0.12	Richard Roztocil-Hofer	Funding
11/16/20	5.920,00	5.920,00	<u>No interest</u>		0.12	Susanne Hoinkes	Funding
11/10/20	5.920,00	5.900,00	<u>No interest</u>		0.12	Annemarie Niklas-Knauer	Funding
11/18/20	5.930,00	5.897,50	<u>No interest</u>		0.12	Josef Gschnitzer	Funding
11/17/20	5.930,00	5.930,00	<u>No interest</u>		0.12	Sabine Petra Münchow	Funding
11/17/20	23.730,00	23.730,00	<u>No interest</u>		0.09	Johannes Othmar Ing. Toppelreiter	Funding
11/17/20	35.000,00	35.000,00	<u>No interest</u>		0.08	MGU Consulting Christian Clement	Funding
11/30/20	5.990,00	5.879,50	<u>No interest</u>		0,12	Waltraud Dr. Pfister	Funding
12/08/20	50.000,00	49.955,00	<u>No interest</u>		0,08	Dan Isalin	Funding
01/17/21	24.884,00	24.884,00	<u>No interest</u>		0.10	Johannes Othmar Ing. Toppelreiter	Funding
01/19/21	12.130,00	12.095,00	<u>No interest</u>		0.10	Ing. Harald Himsl	Funding
01/24/21	30.000,00	40.000,00	<u>No interest</u>		0.10	Simon Wanzenried	Funding
01/24/21	30.000,00	29.982,50	<u>No interest</u>		0.15	Gottfried Kiefer	Funding
01/24/21	45.000,00	44.975,00	<u>No interest</u>		0.10	Rafael Dario Soctoni	Funding
01/29/21	5.000,00	5.000,00	<u>No interest</u>		0.10	Bernhard u. Anita Rappl	Funding
01/29/21	6.050,00	6.050,00	<u>No interest</u>		0.15	Inka Demling	Funding
02/01/21	200.905,00	200.905,00	<u>No interest</u>		0.16	Beton Gold GmbH Oliver Möller	Funding

02/01/21	24.000,00	24.000,00	<u>No interest</u>		0.24	Jan Niclas Berkefeld	Funding
02/01/21	24.000,00	24.000,00	<u>No interest</u>		0.24	Dirk Berkefeld	Funding
02/01/21	27.000,00	26.930,70	<u>No interest</u>		0.12	Malte Commandeur	Funding
02/02/21	30.437,00	30.437,00	<u>No interest</u>		0.10	Waltraud Dr. Pfister	Funding
02/02/21	20.000,00	20.000,00	<u>No interest</u>		0.08	Chris Mönninghof	Funding
02/02/21	20.000,00	19.950,00	<u>No interest</u>		0.08	Jan Papenbrock	Funding
02/02/21	10.000,00	11.726,00	<u>No interest</u>		0.15	Stephan Munk	Funding
02/02/21	6.087,00	6.087,00	<u>No interest</u>		0.10	Barbara Pfister	Funding
02/04/21	50.000,00	50.000,00	<u>No interest</u>		0.15	Daniel Ehler	Funding
02/04/21	20.000,00	20.000,00	<u>No interest</u>		0.08	Thomas Dr. Tork	Funding
02/08/21	78.000,00	77.682,83	<u>No interest</u>		0.15	Stephan Roelli	Funding
02/08/21	15.000,00	15.000,00	<u>No interest</u>		0.15	Yves Dennler	Funding
02/08/21	31.500,00	31.482,00	<u>No interest</u>		0.15	Patrick Buser	Funding
02/17/21	30.000,00	29.627,00	<u>No interest</u>		0.24	Philipp Erik Breitenfeld	Funding
03/10/21	11.920,00	11.724,00	<u>No interest</u>		0.15	Annemarie Niklas-Knauer	Funding
03/16/21	9.600,00	9.567,50	<u>No interest</u>		0,15	Franz Josef Gschnitzer	Funding
03/16/21	360.000,00	200.000,00	<u>No interest</u>		0.15	Barbara Wenk Weber	Funding
03/18/21	12.000,00	12.000,00	<u>No interest</u>		0.15	Manuela Knott	Funding
03/18/21	6.000,00	5.974,00	<u>No interest</u>		0.15	Anne Hergeselle	Funding
03/18/21	14.166,75	14.166,73	<u>No interest</u>		0.15	Susanne Hoinkes	Funding
03/18/21	162.210,00	162.210,00	<u>No interest</u>		0.15	Herzig Holding AG Jean Pierre Herzig	Funding

03/18/21	80.000,00	80.000,00	<u>No interest</u>		0.08	Nico Curman	Funding
03/18/21	5.950,00	5.950,00	<u>No interest</u>		0.15	Niklas Weiland	Funding
03/20/21	18.000,00	17.957,00	<u>No interest</u>		0.15	Karin Jahn- Rothmund	Funding
03/20/21	22.500,00	22.500,00	<u>No interest</u>		0.15	Rudolf Brandt	Funding
03/22/21	64.000,00	63.965,00	<u>No interest</u>		0.15	Susanne Reinhardt	Funding
03/22/21	6.000,00	6.000,00	<u>No interest</u>		0.15	Frank Dörry	Funding
03/23/21	6.000,00	6.000,00	<u>No interest</u>		0.15	Siegfried Unterberger	Funding
03/24/21	10.000,00	10.000,00	<u>No interest</u>		0.15	Gerd Petratschek	Funding
03/24/21	6.000,00	5.964,00	<u>No interest</u>		0.15	Elisabeth Dornhackl	Funding
03/24/21	186.300,0 0	186.300,00	<u>No interest</u>		0.15	Nicole Steinegger	Funding
03/24/21	160.000,0 0	160.000,00	<u>No interest</u>		0.15	Irene Schwegler	Funding
03/25/21	6.000,00	6.000,00	<u>No interest</u>		0.15	Sabine Möller	Funding
03/26/21	53.000,00	52.986,50	<u>No interest</u>		0.15	Bruno Bucher	Funding
03/31/21	5.900,00	5.925,50	<u>No interest</u>		0.15	Karin Benner	Funding
03/31/21	5.900,00	5.900,00	<u>No interest</u>		0.15	Karl Heinz Platzer	Funding
04/01/21	6.000,00	6.000,00	<u>No interest</u>		0.15	Michael Schwaegerl	Funding
04/06/21	5.000,00	4.990,00	<u>No interest</u>		0.15	Regula Buri	Funding
04/19/21	10.000,00	9.977,00	<u>No interest</u>		0.15	Peter Krienbuehl	Funding
03/19/21	12.000,00	12.000,00	<u>No interest</u>		0.15	Hans Joachim Beltzer	Funding
04/25/21	15.000,00	15.000,00	<u>No interest</u>		0.15	Dr Ralf Jauck	Funding
04/19/21	15.000,00	15.000,00	<u>No interest</u>		0.15	Jürgen Poellinger	Funding

04/19/21	15.000,00	15.000,00	<u>No interest</u>		0.15	Olaf Oswina Eitner	Funding
04/26/21	17.860,00	17.860,00	<u>No interest</u>		0.10	Daniel von Lison	Funding

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Jorge Verar
Title: CPA
Relationship to Issuer: Independent Contractor

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
D. Statement of income;
E. Statement of cash flows;
F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
G. Financial notes; and
H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

VITANA-X INC.
FINANCIAL STATEMENTS
JANUARY 31, 2021

Table of Contents

<u>CONSOLIDATED BALANCE SHEETS</u>	<u>2</u>
<u>CONSOLIDATED STATEMENT OF OPERATIONS</u>	<u>3</u>
<u>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</u>	<u>4</u>
<u>STATEMENT OF CASH FLOWS</u>	<u>5</u>
<u>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</u>	<u>7</u>

VITANA-X Inc.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

	January 31, 2021	July 31, 2020
ASSETS		
CURRENT ASSETS		
Cash	\$ 41,457	\$ 55
Accounts Receivable	334,986	
Inventories	223,955	
Due From Related Parties	127,929	143,829
Prepaid Expenses	667	-
TOTAL CURRENT ASSETS	728,994	143,884
FIXED ASSETS (net of depreciation)	48,616	-
TOTAL ASSETS	777,610	143,884
LIABILITIES AND STOCKHOLDERS' DEFICIENCY		
CURRENT LIABILITIES		
Bank Overdraft	24,638	28
Accounts payable and accrued expenses	882,257	155,045
Related party payable	208,001	-
Short term loan	75,622	-
Lease payable	36,280	-
Convertible notes payable	1,014,389	587,135
Derivative liabilities	255,399	255,398
TOTAL CURRENT LIABILITIES	2,496,584	997,606
LOANS PAYABLE	112,391	-
TOTAL LIABILITIES	2,608,975	997,606
STOCKHOLDERS' DEFICIENCY		
Preferred stock; \$0.0001 par value; 10,000,000		
Series A Preferred stocks \$0.0001 par value; 1,000,000 shares designated; 1,000,000 shares issued and outstanding	100	100
Series B Preferred stock; \$0.0001 par value; 1,344,756 shares designated; 1,344,755 and 929,945 shares issued and outstanding	134	134
Common stock; no par value; 5,000,000,000 shares authorized; 1,354,502,045 shares issued and outstanding on January 31, 2021, and July 31, 2020 respectively.	93,545	43,548
Additional paid-in capital	3,985,485	3,985,486
Accumulated deficit	(5,894,545)	(4,882,990)
Comprehensive Income	(16,085)	-
TOTAL STOCKHOLDERS' DEFICIENCY	(1,831,365)	(853,722)
TOTAL LIABILITIES & STOCKHOLDERS' DEFICIENCY	\$ 777,610	\$ 143,884

VITANA-X Inc.
CONSOLIDATED STATEMENT OF OPERATIONS
(UNAUDITED)

	Three months ended January 31,		Six months ended January 31,	
	2021	2020	2021	2020
REVENUES	\$ 413,330	\$ 44,248	\$ 413,330	\$ 61,375
COST OF REVENUES	163,961	-	163,961	-
GROSS PROFIT	<u>249,369</u>	<u>44,248</u>	<u>249,369</u>	<u>61,375</u>
Operating Expenses				
General and Administrative	52,235	14,479	59,470	89,405
Professional and consulting				
Fees	638,548	1,632,220	758,431	3,550,138
Testing and research	9,410	-	9,410	-
Depreciation and				
amortization	228	-	2,478	3,639,543
TOTAL EXPENSES	<u>700,421</u>	<u>1,646,699</u>	<u>829,789</u>	<u>7,279,086</u>
NET OPERATING LOSS	<u>(451,052)</u>	<u>(1,602,451)</u>	<u>(580,420)</u>	<u>(7,217,711)</u>
Other Income (Expenses)				
Gain (loss) from				
change in fair value of				
conversion option				
liability		(129,613)	-	229,996
Loss from foreign				
currency		(2,399)		(5,435)
Gain on debt				
extinguishment		-		453
Interest expense		(14,740)		(190,545)
Financing cost	(6,723)		(6,273)	
Other Income	48,162		48,162	
NET LOSS	<u>(409,613)</u>	<u>\$ (1,749,203)</u>	<u>\$ (538,531)</u>	<u>\$ (7,183,242)</u>
Net loss attributable to				
common shareholders	<u>(409,613)</u>	<u>(1,749,203)</u>	<u>(538,531)</u>	<u>(7,183,242)</u>
NET LOSS PER				
COMMON SHARE –				
BASIC AND DILUTED	<u>(0)</u>	<u>(0)</u>	<u>(0)</u>	<u>(0)</u>
WEIGHTED AVERAGE				
NUMBER OF SHARES				
OUTSTANDING	<u>1,354,502,045</u>	<u>435,482,400</u>	<u>1,354,502,045</u>	<u>380,123,668</u>

VITANA-X Inc.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
(UNAUDITED)

Balances October 31, 2020	Preferred Stock - Series A		Preferred Stock - Series B		Common Stock		Paid-in Capital	Subscription Receivable	Accumulated Deficit	Comprehensive Gain (loss)	Stockholders' Equity (Deficit)
	Number	Amount	Number	Amount	Number	Amount					
Balance at July 31, 2020	1,000,000	\$ 100	1,344,755	\$ 134	435,482,400	\$ 43,548	\$ 3,985,486	\$ -	\$ (4,882,990)		\$ (853,722)
Net loss for the three months ended October 31, 2020	-	-	-	-	-	-	-	-	(128,918)		(128,918)
Balance at October 31, 2020	1,000,000	100	1,344,755	134	435,482,400	43,548	3,985,486	-	(5,011,908)	-	(982,640)
Net effect of acquisition of sub co.					919,019,645	49,997			(473,021)		(423,024)
Foreign currency translation										(16,080)	(16,080)
Net loss for the three months ended January 31, 2021									(409,616)		(409,616)
Balances January 31, 2021	1,000,000	100	1,344,755	134	1,354,502,045	93,545	3,985,486	-	(5,894,545)	(16,080)	(1,831,360)
Balances October 31, 2019											
Balance at July 31, 2019	-	\$ -	929,945	\$ 93	-	\$ -	\$ 1,868,542	\$ (8,857)	\$ (1,117,804)		\$ 741,974
Recapitalization of the Company	1,000,000	100	-	-	371,357,400	37,135	(648,797)	-	-		(611,562)
Common stock issued pursuant to conversion of convertible debt	-	-	-	-	71,125,000	7,113	131,437	-	-		138,550
Reclassification of put premium to equity upon conversion of debt	-	-	-	-	-	-	21,099	-	-		21,099
Issuance of Series B Preferred stock for cash	-	-	19,884	2	-	-	108,892	-	-		108,894
Issuance of Series B Preferred stock for services	-	-	350,364	35	-	-	1,903,065	-	-		1,903,100
Cancellation of common stock pursuant to spin off agreement	-	-	-	-	(7,000,000)	(700)	700	-	-		-
Cash received for subscription	-	-	-	-	-	-	-	8,857	-		8,857
Fair value of stock options issued to a consultant for services	-	-	-	-	-	-	358,500	-	-		358,500
Net loss for the period	-	-	-	-	-	-	-	-	(1,794,496)		(1,794,496)
Balance at October 31, 2019	1,000,000	100	1,300,193	130	435,482,400	43,548	3,743,438	-	(2,912,300)		874,916
Net loss for the three months ended January 31, 2020									(1,749,203)		(1,749,203)
Balances January 31, 2020	1,000,000	\$ 100	1,300,193	\$ 130	435,482,400	\$ 43,548	3,743,438	\$ -	\$ (4,661,503)		\$ (874,287)

See accompanying condensed notes to unaudited consolidated financial statements.

VITANA-X Inc.
CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)

	January 31,	
	2021	2020
OPERATING ACTIVITIES:		
Net loss	\$ (538,531)	\$ (3,543,699)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation and professional fees		358,500
Stock-based conversion fees		1,000
Amortization of prepaid stock-based expenses		2,895,236
Accretion of premium on convertible note		147,688
Amortization and depreciation	2,478	26,662
Gain on debt extinguishment		(453)
Gain from change in fair value of conversion option liability		(229,996)
Changes in operating assets and liabilities:		
Accounts receivables	(334,986)	
Inventories	(223,955)	
Bank overdraft	24,610	
Accounts Payable and accrued expenses	727,212	(166,606)
Lease payable	36,280	
Due From Related Parties	(15,900)	(10,141)
Prepaid expense	(667)	(27,250)
Accounts payable related party	208,001	(54,462)
Accrued interest		17,486
NET CASH USED IN OPERATING ACTIVITIES	(115,459)	(586,035)
CASH FLOWS FROM INVESTING ACTIVITIES		
Advances to related party		(211,755)
Collection of related party advances		152,947
Proceed from acquisition of a subsidiary		47,822
Net cash provided by investing activities	=	(10,986)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from short term loan	75,622	
Proceeds from loans payable	112,391	
Proceeds from issuance of convertible notes	427,254	299,917
Proceeds from sale of Series B Preferred stock		223,119
Collection of subscription receivable		8,857
Issuance of common stock	49,997	
Fixed asset acquired	(51,464)	
Capital adjustment as a result of Vitana-X acquisition		
	(473,024)	
NET CASH PROVIDED BY FINANCING ACTIVITIES	140,776	531,893
Effect of foreign currency translation		-
	16,085	
INCREASE (DECREASE) IN CASH	41,402	(65,128)
CASH-BEGINNING OF PERIOD	55	66,112

VITANA-X Inc.
CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)

CASH-END OF PERIOD

<u>\$</u>	<u>41,457</u>	<u>\$</u>	<u>985</u>
-----------	---------------	-----------	------------

Vitana X Inc.
Notes to Consolidated Financial Statements
For the six months ended January 31, 2021
(Unaudited)

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Vitana X Inc. (formerly GH Capital Inc.) a Florida corporation, was formed on May 5, 2014. The Company is a wellness company specializing in the development and manufacture of health promoting products based on DNA analysis. The Company plans to sell and market nutritional and health promoting products such as energy drinks. On August 21, 2019, the Company changed its fiscal year end from September 30 to July 31 to conform with its subsidiary which was acquired on the same day as discussed below. The Company's former operations were in the business of providing online payment processing services to consumers, primarily in Europe and provided certain consulting services to assist companies in going public.

On March 31, 2019, the Company's Board of Directors approved the increase of the Company's authorized shares for common stock to 5,000,000,000 shares from 490,000,000 shares of authorized shares of common stock. The Company filed Articles of Amendment to its Articles of Incorporation with Florida Secretary of State and requested an effective date of May 1, 2019 for the increase of authorized shares of common stock (see Note 6).

On August 16, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock which designated 1,000,000 shares of preferred stock as Series B Preferred Stock at par value of \$0.0001 (see Note 6). The Company filed Articles of Amendment to its Articles of Incorporation with Florida Secretary of State and requested an effective date of July 20, 2020 for the increase of authorized shares of Series B preferred stock to 1,344,756 from 1,000,000 shares.

On August 21, 2019, the Company entered into a Share Exchange Agreement ("Exchange Agreement") with the shareholders of Vitana Distributions, Inc. ("Vitana") whereby 100% of Vitana's outstanding stock was purchased for certain shares of preferred stock of the Company (see Note 3). Pursuant to the Exchange Agreement, holders of the common stock of Vitana received 1,000,000 shares of the Company's newly designated Series B Preferred Stock (the "Series B Shares") in exchange for each share of common stock of Vitana, on a pro rata basis. The Series B Preferred Stock shall convert into a total amount equaling 80% of the total issued and outstanding common shares, post conversion, on a pro rata basis. The Series B Preferred Stock have no voting rights. Vitana was incorporated on February 11, 2019 in the State of Florida as Vitana-X, Inc. The Company changed its corporate name to Vitana Distributions, Inc. on December 4, 2019.

The closing of the Exchange Agreement was further conditioned upon the resignation of Wolfgang Ruecker, Bane Katic and William Eilers as Directors of the Company and appointment of Matthias Goeth as the Company's Chief Operating Officer and Director and Dirk Richter as the Company's Chairman of the Board of Directors. William Bollander shall remain a Director and Chief Executive Officer of the Company.

Furthermore, simultaneously with the closing, the two majority shareholders of Vitana purchased 1,000,000 shares of the Company's Series A preferred stock from the Company's majority shareholder. The Series A preferred stock have a voting right equal to 65% of all voting rights of all the Company's capital stock.

Upon closing of the Exchange Agreement, Vitana became a wholly owned subsidiary the Company and since the majority shareholders of Vitana obtained majority voting control (at least 65%) of the Company as a result of the above transactions and its operations were spun off to the Company's former majority

owner officer, this transaction was accounted for as a reverse recapitalization of Vitana where Vitana is considered the historical registrant and the historical operations presented will be those of Vitana.

On December 18, 2020, the Company executed the Share Exchange Agreement with Vitana-X Europe. The Company issued the closing payments as described in Note 4. Pursuant to the terms of the purchase agreement, Vitana-X Europe became a wholly owned subsidiary of the Company.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company's interim unaudited consolidated financial statements include the financial statements of Vitana X Inc. and its wholly- owned subsidiary, Vitana Distributions, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

The interim unaudited consolidated financial statements included herein have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). In the opinion of the Company's management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly the results of operations and cash flows for the three months ended October 31, 2020, and the financial position as of October 31, 2020, have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year. Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim condensed financial statements. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with the unaudited Financial Statements and Notes thereto as of and for the year ended July 31, 2020 included in our Annual Report on Form. The July 31, 2020 balance sheet is derived from those financial statements.

Going Concern

These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited consolidated financial statements, for the three months ended January 31, 2021, the Company had a net loss of \$ 409,613 and accumulated deficit of \$5,894,545 and a stockholders' deficit of \$1,831,365.0 It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the issue date of this report. The Company is in the process of building its customer base and expects to generate increased revenues. The Company is seeking to raise capital through additional debt and/or equity financings to fund its operations in the future.

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital. Although the Company has historically raised capital from sales of common stock and debt financing, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional debt in the near future, management expects that the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates. Included in these estimates are assumptions used in determining the fair value of derivative liabilities, valuation allowance for deferred tax assets and the valuation of stock issued for services or upon conversion of debt.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents. The Company places its cash with high credit quality financial institutions. The Company's accounts at these institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to \$250,000. As of January 31, 2021 and July 31, 2020, the Company had not reached bank balances exceeding the FDIC insurance limit on interest bearing accounts. To reduce its risk associated with the failure of such financial institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits.

Accounts Receivable

The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts at January 31, 2021 and July 31, 2020 no provision was necessary.

Inventory and Cost of Sales

Inventories are stated at the lower of cost or realizable value, using the average cost method. When an impairment indicator suggests that the carrying amounts of inventories might not be recoverable, the Company reviews such carrying amounts and estimates the net realizable value based on the most reliable evidence available at that time. An impairment loss is recorded if the net realizable value is less than the carrying value. Impairment indicators considered for these purposes are, among others, obsolescence, decrease in market prices, damage and a firm commitment to sell.

Property and Equipment

Property and equipment are stated at cost. Major renewals and improvements are charged to the asset accounts while replacements, maintenance and repairs that do not improve or extend the lives of the respective assets are expensed. At the time property and equipment are retired or otherwise disposed of, the asset and related accumulated depreciation accounts are relieved of the applicable amounts. Gains or losses from retirements or sales are credited or charged to income.

Long-Lived Assets

The Company accounts for its long-lived assets in accordance with Accounting Standards Codification ("ASC") 360, Property, Plant and Equipment. ASC 360 requires that long-lived assets be reviewed for impairment at least annually, or whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset's carrying value and fair value or disposable value.

Beneficial Conversion Feature of Convertible Notes Payable

The Company considers whether a beneficial conversion feature ("BCF") exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note. The BCF of a convertible note is a reduction of the carrying amount of the convertible note, as a debt discount, and is credited to additional paid-in-capital. Such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.

A contingent beneficial conversion feature in a convertible notes payable with conversion terms that change upon the occurrence of a future event (ex: fair value of the underlying stock declines after the note issuance date) is recognized when the contingency is resolved.

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount:

- i. Identification of the promised goods in the contract.
- ii. Determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract.
- iii. Measurement of the transaction price, including the constraint of variable consideration.
- iv. Allocation of the transaction price of the performance obligations; and
- v. Recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606, Revenue Recognition, at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligations when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time typically upon delivery.

Fair value of financial instruments and fair value measurements

The Company adopted Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results but did expand certain disclosures.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.

These inputs are prioritized below:

- Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
- Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
- Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The estimated fair value of certain financial instruments, including accounts receivable, prepaid expense and other current assets, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

The Company Accounts for the Following Instruments at Fair Value:

A roll forward of the Level 3 Derivative Liabilities

Balance at July 31, 2020	\$ 255,398
Reduction of liability included in gain on debt extinguishment	-
Gain from change in fair value of conversion option liabilities	-
Balance January 31, 2021	<u>\$ 255,398</u>

Derivative Liabilities

The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 815-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded conversion options be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company,

the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise and repayment, the respective derivative liability is marked to fair value at the conversion, repayment or exercise date, and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment.

Income Taxes

The Company accounts for income taxes pursuant to the provision of ASC 740-10, "Accounting for Income Taxes" ("ASC 740-10"), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach require the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

Tax positions that meet the more likely than not recognition threshold is measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

The Company has adopted ASC 740-10-25, "Definition of Settlement", which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

Stock-Based Compensation

The Company accounts for employee stock-based compensation in accordance with ASC 718-10, "*Share-Based Payment*," which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options, restricted stock awards, and employee stock purchases based on estimated fair values.

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to non-employees (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation-Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to non-employees for goods and services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This standard will be effective for financial statements issued by public companies for the annual and interim periods beginning after December 15, 2018. Early adoption of the standard is permitted. The standard will be applied in a retrospective approach for each period presented. Management adopted this standard at inception on February 11, 2019.

Determining Fair Value Under ASC 718-10

The Company estimates volatility based upon the historical stock price of the Company and estimates the expected term. The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company's determination of fair value using an option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables.

For employee stock options using the simplified method for employees and directors and the contractual term for non-employees. The risk-free rate is determined based upon the prevailing rate of United States Treasury securities with similar maturities.

Loss per Common Share and Common Share Equivalent

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period.

The following potentially dilutive equity securities outstanding as of October 31, 2020 and July 31, 2020 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive:

	January 31, 2021	July 31, 2020
Common shares issuable under:		
Convertible shares	486,254,900	483,579,978
Warrants	<u>102,040,816</u>	<u>102,040,816</u>
Total	<u>588,295,716</u>	<u>585,620,794</u>

Leases

In February 2016, the Financial Accounting Standards Board ("FASB") issued ASU 2016-02, *Leases* (Topic 842). The updated guidance requires lessees to recognize lease assets and lease liabilities for most operating leases. In addition, the updated guidance requires that lessors separate lease and non-lease components in a contract in accordance with the new revenue guidance in ASC 606. The updated guidance is effective for interim and annual periods beginning after December 15, 2018.

At inception, on February 11, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company's assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use ("ROU") assets and lease liabilities for short-term leases that have a term of 12 months or less.

Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the consolidated statements of operations.

Foreign Currency Transactions

The reporting and functional currency of the Company is the U.S. dollar. Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of the Company.

Recent Accounting Pronouncements

From time to time, the FASB or other standards setting bodies will issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of an Accounting Standards Update ("ASU").

In August 2018, the FASB issued ASU 2018-13, "Changes to Disclosure Requirements for Fair Value Measurements", which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect ASU 2018-13 to have a material impact on its accounting and disclosures.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

NOTE 3 – CONVERTIBLE NOTES PAYABLE

At January 31, 2021 and July 31, 2020, the components of the convertible promissory notes, net consisted of the following:

	January 31, 2021	July 31, 2020
Principal of convertible notes	\$ 1,014,389	\$ 441,698
Debt premium liability	-	147,688
Unamortized debt discount	-	(2,250)
Convertible notes payable, et current	<u>\$ 1,014,389</u>	<u>\$ 587,136</u>

NOTE 4 – STOCK PURCHASE AGREEMENT

On December 18, 2020, the Company entered into a Share Exchange Agreement with the shareholder of Vitana-X Europe AG, a Swiss Corporation to purchase all of the issued and outstanding equity of Vitana-X Europe AG. The Company acquired Vitana-X Europe to expand its operations.

The Share Exchange Agreement closed on December 21, 2020 and Vitana-X USA issued 1,000,000 shares of Vitana-X USA common stock, no par value to shareholders of Vitana-X Europe. As an additional consideration for the share exchange transaction described herein, and at such time that Vitana-X USA has successfully implemented a reverse stock split, Vitana-X USA shall issue certain customers of Vitana X Europe identified in Schedule 1.2 of the exchange agreement a number of common shares, pro rata, equal to \$0.08 per share described as "incentive Shares" described in Schedule 1.2.

The following unaudited pro forma financial results reflects the historical operating results of the Company, including the unaudited pro forma results of Vitana-X Europe for the six months ended January 31, 2021, as if this business combination had occurred as of August 1, 2020. The pro forma financial information set forth below reflects adjustments to the historical data of the Company to give effect to the Vitana-X Europe acquisition and the related equity issuances as if each had occurred on August 1, 2020. The pro forma information presented below does not purport to represent what the actual results of operations would have been for the period indicated, nor does it purport to represent the Company's future results of operations.

	Six months ended January 31, 2021
Gross Revenue	\$ 1,570,215
Net Revenue	\$ 393,552
Net Loss	\$ 154,759
Net loss per common shares	\$ (0.00041)
Weighted average shares common outstanding	1,354,502,045

The calculations of pro forma net revenue and pro forma net loss give effect to the Vitana-X business combination for the six months ended January 31, 2021 based on the historical net revenue and net income (loss), as applicable, of Vitana-X Europe. The operations for the six months ended January 2021 are included in the accompanying statement of operations and comprehensive income. It does not give account to all purchase accounting adjustments as the purchase accounting has not been finalized. The Company has begun to assess the fair value of the various net assets acquired but has not yet completed this

assessment. The Company is also in the process of identifying other intangible assets, such as customer relationships and know-how that may need to be recognized. Once identified, these other intangible assets, if any, will be recorded at their fair values. The Company is working to finalize the allocations as quickly as possible and anticipates that the allocation will not be final for approximately six months. Any adjustments necessary may be material to the consolidated balance sheet but should not have a material impact to the January 31, 2021 reported operating results or cash flows.

NOTE 5 – STOCKHOLDERS' EQUITY (DEFICIT)

Preferred Stock

The Company has 10,000,000 shares of preferred stock authorized. Preferred stock may be issued in one or more series. The Company's board of directors is authorized to issue the shares of preferred stock in such series and to fix from time to time before issuance thereof the number of shares to be included in any such series and the designation, powers, preferences and relative, participating, optional or other rights, and the qualifications, limitations or restrictions thereof, of such series.

Series A Preferred Stock

On March 8, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock which designated 1,000,000 shares of preferred stock as Series A Preferred Stock at par value of \$0.0001 (see Note 1).

The Series A Preferred Stock Certificate of Designation includes:

- a par value of \$0.0001 per share and 1,000,000 designated shares of Series A preferred and is not convertible,
- the Series A preferred stock shall have voting rights equal to exactly 65% of all voting rights available at the time of any vote, including Series A preferred stock
- the Series A preferred stock shall rank senior to the Company's common stock and to all other classes and series of equity securities of the Company which by their terms do not rank senior to the Series A preferred stock and shall be subordinate to and rank junior to all indebtedness of the Company now or hereafter outstanding,
- Series A preferred holders shall be entitled to receive out of the assets of the Company whether such assets are capital or surplus, for each share of Series A preferred stock, an amount equal to the holder's pro rata share of the assets and funds of the Company to be distributed, less any amount distributed to the holders of the Series A preferred stock, assuming their conversion of Series A preferred stock to common stock and if the assets of the Company shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full,
- No dividends shall be declared or paid on the Series A preferred stock

As of January 31, 2020, the Company had 1,000,000 shares of Series A preferred stock issued and outstanding.

Series B Preferred Stock

On August 16, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B preferred stock which designated 1,000,000 shares of preferred stock as Series B preferred stock at par value of \$0.0001 (see Note 1). On July 20, 2020, the Company's Board of Directors approved the increase of the Company's authorized shares for Series B preferred stock to 1,344,756 shares from 1,000,000 shares of authorized shares of Series B preferred stock.

Shares of Series B Preferred stock granted during the period from February 11, 2019 and July 20, 2020 were considered issuable, and not issued until the authorized shares were increased on July 20, 2020.

The Series B Preferred Stock Certificate of Designation, as amended, includes:

- a par value of \$0.0001 per share and 1,000,000 designated shares of Series B with no voting rights,
- the Series B preferred stock shall rank senior to the Company's common stock and to all other classes and series of equity securities of the Company which by their terms do not rank senior to the Series B preferred stock and shall be subordinate to and rank junior to all indebtedness of the Company now or hereafter outstanding,
- Series B preferred holders shall be entitled to receive out of the assets of the Company whether such assets are capital or surplus, for each share of Series B preferred stock, an amount equal to the holder's pro rata share of the assets and funds of the Company to be distributed, less any amount distributed to the holders of the Series B preferred stock, assuming their conversion of Series B preferred stock to common stock and if the assets of the Company shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full,
- No dividends shall be declared or paid on the Series B preferred stock,
- The Series B preferred stock shall be automatically converted upon the date where in a reverse stock split is deemed effective by the Financial Industry Regulatory Authority ("FINRA"). Each shares of Series B preferred stock shall automatically convert in a number of shares of common stock equal to its pro-rata portion of 80% of the total issued and outstanding common shares, post conversion, to be issued to each holder on a pro-rata portion of the total issued and outstanding Series B preferred stock.

Issuance of Series B preferred stock

- During the six months ended October 31, 2019, the Company issued an aggregate of 19,884 shares of the Company's Series B preferred stock to various investors for cash, with the Company receiving total proceeds of \$108,894 or \$5.48 per share.
- During the three months ended October 31, 2019, the Company issued an aggregate of 350,364 shares of the Company's Series B preferred stock to various consultants for consulting, business advisory, and corporate development services to be rendered. The Company valued the shares of preferred stock at the fair value of approximately \$5.43 per share or \$1,903,100 based on the sales of preferred stock on recent private placements on the dates of grants and such value is being recognized over the terms of the service period.

- During the three months ended January 31, 2020, the Company issued an aggregate of 21,029 shares of the Company's Series B preferred stock to various investors for cash, with the Company receiving total proceeds of \$114,225 or \$5.43 per share.
- During the three months ended January 31, 2020, the Company issued an aggregate of 23,533 shares of the Company's Series B preferred stock to various consultants for consulting, business advisory, and corporate development services to be rendered. The Company valued the shares of preferred stock at the fair value of approximately \$5.43 per share or \$127,827 based on the sales of preferred stock on recent private placements on the dates of grants and such value is being recognized over the terms of the service period.

Increase in Series B Preferred Stock Authorized Shares

On July 20, 2020, the Company's Board of Directors approved the increase of the Company's authorized shares for Series B preferred stock to 1,344,756 shares from 1,000,000 shares of authorized shares of Series B preferred stock.

As of January 31, 2021, had 1,344,755 shares of Series B preferred stock issued and outstanding, respectively.

Common Stock

Common stock issued pursuant to recapitalization

In connection with the Exchange Agreement, the company is deemed to have issued 1,000,000 shares of common stock which represents the purchase price for acquiring Vitana-X Europe. The company have a reserve 2,330,394,909 shares of common stock for issuance to shareholders of Vitana-x Europe and convertible note holders pursuant the share exchange agreement

NOTE 6 – COMMITMENTS AND CONTINGENCIES

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 ("2017 Tax Act"). Corporate taxpayers may carryback net operating losses (NOLs) originating between 2018 and 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carryforwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for 2019 and 2020. The CARES Act allows taxpayers with alternative minimum tax credits to claim a refund in 2020 for the entire amount of the credits instead of recovering the credits through refunds over a period of years, as originally enacted by the 2017 Tax Act.

In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation. The enactment of the CARES Act did not result in any material adjustments to our income tax provision.

NOTE 7 – SUBSEQUENT EVENTS

The company has evaluated subsequent events for recognition and disclosure through August 6, 2021 which is the date the financial statements were available to be issued. No other matters were identified affecting the accompanying financial statements and related disclosures

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Vitana-X, Inc.'s (OTC: VITX) Vitana-X, an international wellness company specializing in the development and manufacture of health-promoting products based on DNA analysis. As an industry pioneer, it offers its customers opportunities to lead a healthier life. Vitana-X offers comprehensive programs for greater well-being, fitness and health by helping you achieve the desired results and offering exercises that fit your body type. Vitana-X wants to support people in their healthy development and be their reliable partner for their full potential. Vitana-X comes from two worlds and wants to unite them in the future – science and the challenges of daily life, so that its customers can continue to care for other areas of life without sacrificing a healthy life

- B. Please list any subsidiaries, parents, or affiliated companies.

VITANA-X Europe AG
Zugerstrasse 76b
CH- 6340 Baar
Switzerland

- C. Describe the issuers' principal products or services.

Energy Drinks
Hydrating creams
Toothpaste

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties, or facilities, clearly describe them as above and the terms of their leases.

N/A

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer’s securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Alois Anichofer</u>	<u>CEO</u>	Eugendorf, Austria	<u>0</u>	<u>Restricted</u>	<u>0.00</u>	
<u>Dirk Richter</u>	<u>Director</u>	<u>Larnaca, Cvprus</u>	<u>25,000,000</u>	<u>Restricted</u>	<u>28.098%</u>	
<u>Bernhard Sammer</u>	<u>Director</u>	<u>Gmunden, Austria</u>	<u>25,000,000</u>	<u>Restricted</u>	<u>28.098%</u>	
<u>Leonardo Management and Consulting LLC</u>	<u>5% Shareholder</u>	<u>Lanarca, Cyprus</u>	<u>10,000,000</u>	<u>Restricted</u>	<u>11.239%</u>	<u>Control Person: Dirk Richter</u> <u>Address: 42 Arch. Makariou Avenue Harbour View Residence Fiat 701 6017 Larnaca Cvprus</u>
Robert Schimanko	<u>5% Shareholder</u>	<u>Sihlbrugg, Switzerland</u>	<u>5,000,000</u>	<u>Restricted</u>	<u>5.620%</u>	

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name:

Firm:

Address 1:

Address 2:

Phone:
Email:

Accountant or Auditor

Name:
Firm:
Address 1:
Address 2:
Phone:
Email:

Investor Relations

Name: N/A
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: N/A
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Alois Anichhofer certify that:

1. I have reviewed this annual report and disclosure of Vitana-X Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

08/06/2021

/s/Alois Anichhofer
Chief Executive Officer

Principal Financial Officer:

I, Alois Anichhofer certify that:

1. I have reviewed this annual report and disclosure of Vitana-X Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

08/06/2021

/s/Alois Anichhofer
Chief Financial Officer